Shveta Gupta
Pediatric Hematology-Oncology · Orlando, FLNPI 1366881468
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $521,901 of the $714,328 with a category attached, or 73.1%. 18 manufacturers reported payments, led by Novo Nordisk at 52.0% of the total. Among pediatric hematology-oncology clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 462 payments — averaging $1546.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$371K
- Sanofi$242K
- CSL Behring$26K
- Bayer$19K
- Global Blood Therapeutics, Inc.$18K
- Genentech USA, Inc.$13K
- plus $25K from 12 others
Across 241 payments — averaging $519.61 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Bayer$61K
- Pfizer$24K
- Novo Nordisk AS$21K
- HEMA Biologics, LLC$10K
- Octapharma USA, Inc.$5K
- F. Hoffmann-la Roche AG$4K
What the payments were for
- Consulting fees$103,27114%
- Speaking & faculty fees$521,90173%
- Travel & lodging$79,06811%
- Food & beverage$9,9771%
- Education$1120%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 201 | $371,127 |
| Sanofi | 131 | $241,829 |
| CSL Behring | 32 | $25,684 |
| Bayer | 19 | $19,388 |
| Global Blood Therapeutics, Inc. | 18 | $18,084 |
| Genentech USA, Inc. | 18 | $13,109 |
| Octapharma USA, Inc. | 20 | $8,310 |
| Novartis | 9 | $6,643 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $4,078 |
| HEMA Biologics, LLC | 1 | $2,500 |
| Chiesi USA, Inc. | 1 | $1,605 |
| Pfizer | 2 | $1,350 |
| Bio Products Laboratory USA, Inc. | 1 | $172 |
| Abiomed | 1 | $135 |
| Genentech, Inc. | 1 | $133 |
| Sobi, Inc | 1 | $116 |
| Biomarin Pharmaceutical Inc. | 1 | $43 |
| Daiichi Sankyo Inc. | 1 | $22 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ALTUVIIIO$204,709
- Esperoct$65,901
- REBINYN$62,227
- Alhemo$38,948
- NovoSeven$35,840
- NovoSeven RT$30,785
- Jivi$17,196
- Idelvion$17,060
- OXBRYTA$14,740
- HEMLIBRA$12,976
- ALPROLIX$8,907
- HEMGENIX$6,426
- NUWIQ$4,138
- WILATE - VON WILLEBRAND FACTOR/COAGULATION FACTOR VIII COMPLEX (HUMAN)$3,848
- ELOCTATE$3,413
- SevenFact$2,500
- ADVATE$2,478
- ADAKVEO$2,189
- Kovaltry$1,902
- QFITLIA$1,847
How this compares
$714,328 in reported general payments places this provider in the 95th percentile of 132 pediatric hematology-oncology providers in Florida.
See all pediatric hematology-oncology providers in Florida →
Other pediatric hematology-oncology in Orlando
- Jaime Libes-BanderOrlando$133K
- Dennis Borrero RamosOrlando$56K
- Amy SmithOrlando$45K
- Fouad HajjarOrlando$21K
- Amina RafiqueOrlando$11K
- Brian TulliusOrlando$5K
- Robert SutphinOrlando$1K
- Christian Nieves RiveraOrlando$1K
- Vincent GiustiOrlando$712
- Guillermo DeanguloMiami$929K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.